美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · PCRX近 30 天 3 則 · 第 1 / 1 頁
- Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
- Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
- PharmaCorp Rx Inc. Announces Board and Committee Changes
- Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
- Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
- Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
- Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic ...
- Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
- Pacira BioSciences Reports Second Quarter 2026 Financial Results
- Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
- Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。